Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company with a market capitalization of $20.21 million, has announced significant progress in the development of HT-001, a novel topical therapeutic aimed at treating skin toxicities associated with cancer treatments. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 15.08, indicating robust short-term financial stability. The company is set to present a case study and Phase 2a interim clinical trial results at an upcoming Key Opinion Leader (KOL) event.
HT-001 targets the common side effects of epidermal growth factor receptor (EGFR) inhibitor therapies, such as rash and inflammation, that often lead patients to reduce or halt their cancer treatments. The drug is being developed to improve the quality of life for patients and ensure they can continue their essential oncology treatments uninterrupted.
The need for supportive care drugs like HT-001 is growing, as the chemotherapy drug market is expected to expand from USD 10.87 billion in 2024 to USD 18.35 billion by 2031. Despite existing supportive care drugs, severe conditions like Acral erythema, also known as hand-foot syndrome, demonstrate the need for new or improved treatment options. InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $4 to $5, significantly above current trading levels. Discover more valuable insights about HOTH and other healthcare companies with an InvestingPro subscription.
Robb Knie, CEO of Hoth Therapeutics, expressed optimism about HT-001, stating that it represents a pioneering treatment for the skin toxicities associated with EGFR therapies. The KOL event will feature expert commentary from dermatology specialists, who will discuss the urgent clinical need for HT-001 and share preliminary data on its safety and efficacy.
In addition to the clinical advancements, Hoth Therapeutics has also received a USPTO Filing Receipt for a new patent application for HT-001’s unique formulation, enhancing its intellectual property strategy and market protection.
The KOL event, scheduled for June 24, 2025, will provide updates on the company’s pipeline progress and the ongoing Phase 2 trial. The event is open to investors, media, potential partners, and healthcare professionals. The company’s stock has shown remarkable momentum, posting a 76.41% return in the past week and an impressive 104.52% gain year-to-date, as tracked by InvestingPro, which offers real-time updates and comprehensive financial analysis for serious investors.
This news is based on a press release statement from Hoth Therapeutics, Inc. The company continues to focus on developing innovative treatments with the goal of improving patient quality of life, advancing from early-stage research to clinical testing.
In other recent news, Hoth Therapeutics announced significant progress across multiple fronts. The company reported promising preclinical results for its Alzheimer’s drug candidate, HT-ALZ, which improved cognitive functions and reduced neuroinflammation in disease models. Additionally, Hoth Therapeutics shared positive interim results from its Phase 2a clinical trial of HT-001, showing a 50% reduction in pruritus severity in patients with skin toxicities from cancer treatments.
In the realm of intellectual property, Hoth Therapeutics confirmed the payment of fees for a significant international patent application related to hair loss treatment, marking a procedural milestone in its patent strategy. Furthermore, the company secured a new patent from the Japan Patent Office for RNA-based cancer therapies targeting the KIT gene, enhancing its position in RNA therapeutics.
The company also revealed notable preclinical results for HT-KIT, an antisense oligonucleotide therapy, showing over 80% reduction in KIT expression and tumor growth inhibition in certain cancer models. These developments underscore Hoth Therapeutics’ ongoing efforts in advancing its pipeline and securing intellectual property rights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.